NCT04609566 2026-03-16Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsSeagen Inc.Phase 2 Completed161 enrolled
NCT03007030 2025-11-10Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by SurgeryM.D. Anderson Cancer CenterPhase 2 Recruiting55 enrolled